Not logged in Share Save
DISSECTING THE TUMOR MICROENVIRONMENT OF ADVANCED UROTHELIAL CARCINOMA PRE AND POST ENFORTUMAB VEDOTIN ± PEMBROLIZUMAB Raizenne, Brendan Lapointe; Nechiporuk, Tamilla; Ding, Cornelia; Dias, Mikhail; Yuxin, Yang; Chou, Jonathan; Friedlander, Terence; Porten, Sima; Meng, Maxwell; Quigley, David; Koshkin, Vadim; Huang, Franklin; Chu, Carissa Share Save
CD46 AS A THERANOSTIC TARGET IN BLADDER CANCER: EXPRESSION PROFILING AND PRE-CLINICAL VALIDATION OF [89ZR]ZR-DFO-YS5 PET IN BLADDER CANCER Kornberg, Zachary Thomas; Raveendran, Athira; Delavan, Henry M.; Dougherty, William; Saxena, Shivani; Nechiporuk, Tamilla; Bidlingmaier, Scott; Wang, Chunyue; Greenland, Nancy; Friedlander, Terence W.; Porten, Sima P.; Liu, Bin; Chu, Carissa E.; Flavell, Robert R.; Chou, Jonathan Share Save
EXAMINING THE IMPACT OF TGF-B ACTIVITY ON FIBROBLAST INFILTRATION AND IMMUNE EXCLUSION IN MUSCLE-INVASIVE BLADDER CANCER Gupta, Shilpa; De Jong, Joep J.; Alshalalfa, Mohammed; Chou, Jonathan; Koshkin, Vadim; Friedlander, Terence W.; Oh, David; Chu, Carissa E.; Mar, Nataliya; Sasse, Alexander; Wong, Anthony; Proudfoot, James A.; Davicioni, Elai; Seyedin, Steven Neema Share Save
Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) plus pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; Brown, J. R.; McKay, R. R.; Merchan, J. R.; Srinivas, S.; Shetty, A.; Homet Moreno, B.; Davis, G.; Wirtz, H.; Zhu, Y.; Milowsky, M. I. Share Save
Modulating the PPARγ pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T cell therapy Chang, Kevin; Delavan, Henry M.; Zhu, Jun; Kasap, Corynn; Yip, Elizabeth; Lodha, Roshan; Liao, Sheng-You; Porten, Sima; Friedlander, Terence; Koshkin, Vadim; Feng, Felix; Wiita, Arun; Lee, John; Chu, Carissa E.; Chou, Jonathan Share Save
Bladder Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines Flaig, Thomas W.; Spiess, Philippe E.; Abern, Michael; Agarwal, Neeraj; Bangs, Rick; Buyyounouski, Mark K.; Chan, Kevin; Chang, Sam S.; Chang, Paul; Friedlander, Terence; Greenberg, Richard E.; Guru, Khurshid A.; Herr, Harry W.; Hoffman-Censits, Jean; Kaimakliotis, Hristos; Kishan, Amar U.; Kundu, Shilajit; Lele, Subodh M.; Mamtani, Ronac; Mian, Omar Y.; Michalski, Jeff; Montgomery, Jeffrey S.; Parikh, Mamta; Patterson, Anthony; Peyton, Charles; Plimack, Elizabeth R.; Preston, Mark A.; Richards, Kyle; Sexton, Wade J.; Siefker-Radtke, Arlene O.; Stewart, Tyler; Sundi, Debasish; Tollefson, Matthew; Tward, Jonathan; Wright, Jonathan L.; Cassara, Carly J.; Gurski, Lisa A. Share Save
Responders to combination radiation and PD-1 blockade demonstrate reduced myeloid immunosuppression and enhanced interferon signaling in oligometastatic prostate cancer patients Fan, Zenghua; Oh, David Y.; Wong, Anthony; Shinohara, Katsuto; Nguyen, Hao; Hwang, Caleb; Chang, Hewitt; Starzinski, Alec; Li, Tony; De Leon, Christopher; Gin, Marissa; Van Allen, Eliezer; Zhang, Li; Aggarwal, Rahaul R.; Friedlander, Terence W.; Small, Eric J.; Feng, Felix Y.; Fong, Lawrence Share Save
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201 Necchi, A.; Pouessel, D.; Leibowitz, R.; Gupta, S.; Flechon, A.; Garcia-Donas, J.; Bilen, M. A.; Debruyne, P. R.; Milowsky, M. I.; Friedlander, T.; Maio, M.; Gilmartin, A.; Li, X.; Veronese, M. L.; Loriot, Y. Share Save
Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer Koshkin, Vadim S.; Kumar, Vipul; Kline, Brad; Escobar, Domenique; Aslam, Maya; Cooperberg, Matthew R.; Aggarwal, Rahul R.; de Kouchkovsky, Ivan; Chou, Jonathan; Meng, Maxwell, V; Friedlander, Terence; Porten, Sima; Hope, Thomas A. Share Save
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab Hoimes, Christopher J.; Flaig, Thomas W.; Milowsky, Matthew, I; Friedlander, Terence W.; Bilen, Mehmet Asim; Gupta, Shilpa; Srinivas, Sandy; Merchan, Jaime R.; Mckay, Rana R.; Petrylak, Daniel P.; Sasse, Carolyn; Moreno, Blanca Homet; Yu, Yao; Carret, Anne-Sophie; Rosenberg, Jonathan E. Share Save
A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinumbased chemotherapy (chemo) Gupta, S.; Alhalabi, O.; Bamias, A.; Bellmunt, J.; Castellano Gauna, D. E.; Bedke, J.; Friedlander, T.; Garmezy, B.; Grivas, P.; Huddart, R. A.; Necchi, A.; Powles, T. B.; Puente, J.; Da Rosa, D. A. R.; Wang, F.; Lambertini, C.; Andreev-Drakhlin, A.; Fasso, M.; Loriot, Y. Share Save
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma) Drakaki, Alexandra; Powles, Thomas; Bamias, Aristotelis; Martin-Liberal, Juan; Shin, Sang Joon; Friedlander, Terence; Tosi, Diego; Park, Chandler; Gomez-Roca, Carlos; Lobbedez, Florence Joly; Castellano, Daniel; Morales-Barrera, Rafael; Moreno-Candilejo, Irene; Flechon, Aude; Yuen, Kobe; Rishipathak, Deepali; Dupree, Kelly; Young, Fiona; Michielin, Francesca; Shemesh, Colby S.; Steinberg, Elizabeth E.; Williams, Patrick; Lee, Jae Lyun Share Save
Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study Wang, Elizabeth Y.; Borno, Hala T.; Washington III, Samuel L.; Friedlander, Terence; Zhang, Sylvia; Trejo, Evelin; Van Blarigan, Erin L.; Chan, June M.; Shariff-Marco, Salma; Beatty, Alexis L.; Kenfield, Stacey A. Share Save
Share Save
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer Jindal, Tanya; Zhu, Xiaolin; Bose, Rohit; Kumar, Vipul; Maldonado, Edward; Deshmukh, Prianka; Shipp, Chase; Feng, Stephanie; Johnson, Michelle S.; Angelidakis, Austin; Kwon, Daniel; Borno, Hala T.; de Kouchkovsky, Ivan; Desai, Arpita; Aggarwal, Rahul; Fong, Lawrence; Small, Eric J.; Wong, Anthony; Porten, Sima; Chou, Jonathan; Friedlander, Terence; Koshkin, Vadim S. Share Save
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells Chou, Jonathan; Trepka, Kai; Sjostrom, Martin; Egusa, Emily A.; Chu, Carissa E.; Zhu, Jun; Chan, Emily; Gibb, Ewan A.; Badura, Michelle L.; Contreras-Sanz, Alberto; Stohr, Bradley A.; Meng, Maxwell, V; Pruthi, Raj S.; Lotan, Yair; Black, Peter C.; Porten, Sima P.; Koshkin, Vadim S.; Friedlander, Terence W.; Feng, Felix Y. Share Save
CLINICAL AND PHARMACODYNAMIC BIOMARKER RESULTS FROM PORTER, A MULTI-COHORT PHASE 1 PLATFORM TRIAL OF COMBINATION IMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS Galsky, Matthew; Autio, Karen; Wentzel, Kristopher; Graff, Julie; Friedlander, Terence; Densmore, Julie; Cabanski, Christopher; Shotts, Kristin; Howes, Tim; Yu, Jia; Eisenbeisz, Elaine; Spasic, Marko; Maddock, Stephen; DaSilva, Diane; Kumar, Dinesh; Moore, Jonni; Schretzenmair, Richard; Lata, Jennifer; Xu, Arron; Reuschel, Emma; Wani, Snehal; Morrow, Matthew; Skolnik, Jeffrey; Santulli-Marotto, Sandra; Padron, Lacey; Butterfield, Lisa; LaVallee, Theresa; Bucktrout, Samantha; Yellin, Michael; Keler, Tibor; Salvador, Lisa; O'Donnell-Tormey, Jill; Lucey, Vanessa; Fairchild, Justin; Dugan, Ute; Bhardwaj, Nina; Subudhi, Sumit; Fong, Lawrence Share Save
Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study Grivas, P.; Agarwal, P. K.; Al-Ahmadie, H.; Friedlander, T.; Geynisman, D.; Hussain, I.; Lotan, Y.; Morgans, A. K.; Tesic-Schnell, M.; Meeks, J. Share Save
Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) Rosenberg, J. E.; Milowsky, M.; Ramamurthy, C.; Mar, N.; Mckay, R. R.; Friedlander, T.; Ferrario, C.; Bracarda, S.; George, S.; Moon, H.; Geynisman, D.; Petrylak, D. P.; Borchiellini, D.; Burgess, E. F.; Rey, J. P. Maroto; Carret, A-S.; Yu, Y.; Guseva, M. V.; Moreno, B. Homet; O'Donnell, P. H. Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
